iShares Nasdaq Biotechnology ETFFind Ratings Reports
- Last Ratings Update:04/30/2017
- Price as of 04/30/2017 :$297.64
- Net Assets:$5,424.3 Million
- Peer Rank:26 of 35
- Investment Rating:D+
We rate iShares Nasdaq Biotechnology at D+. The fund invests approximately 100% of its assets in stocks and may be considered for investors seeking a Sector - Health/Biotechnology strategy.
POSITIVES AND RISKS
Total return ranks above peers over the last three years. The iShares Nasdaq Biotechnology has returned an annual rate of 7.13% since inception. More recently, the fund has generated a total return of 19.80% in the last five years, 9.31% in the last three years, and 11.34% in the last year. How does that compare to other equity funds? In the last five years, it has outperformed 96% of them. It has also outpaced 74% of its competitors on a three year basis and 47% of them over the last year for the period ending 4/30/2017. On a year to date basis, IBB has returned 12.27%.
Downside risk has been below average. IBB has a draw down risk of -33.58%, which is the largest price decline experienced over the last three years. This fund has a three year standard deviation of 25.6%. This fund has experienced excessive volatility in its monthly performance over the last 36 months. As of 4/30/2017, the fund was trading at a price of $297.64, which is 0.2% below its 52-week high of $298.31 and 4.1% above its 52-week low of $285.85.
Low expense ratio helps performance. On total assets of $5.42 billion, IBB maintains a low expense ratio compared to its Sector - Health/Biotechnology peers of just 0.47% to cover all operating costs. Brokerage costs for the fund to buy and sell shares are not included in the expense ratio. As IBB is an exchange traded fund, it has no front end or back end load.
The iShares Nasdaq Biotechnology is managed by Diane Hsiung at BlackRock Fund Advisors. This fund is one of 306 BlackRock Fund Advisors exchange-traded funds launched since 3/12/1996 that we track.